Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity.

Zhang Y, Mariz FC, Sehr P, Spagnoli G, Koenig KM, Çelikyürekli S, Kreuziger T, Zhao X, Bolchi A, Ottonello S, Müller M

NPJ vaccines, 2024

doi:10.1038/s41541-024-00832-0.

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.

Bhatla N, Muwonge R, Malvi SG, Joshi S, Poli URR, Lucas E, Esmy PO, Verma Y, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Vashist S, Mishra G, Jadhav R, Siddiqi M, Anantharaman D, Panicker G, Butt J, Sankaran S, Kannan TPRA, Varghese R, Kartha P, Pillai MR, Waterboer T, Müller M, Sehr P, Unger ER, Sankaranarayanan R, Basu P

Human vaccines & immunotherapeutics, 2023

doi:10.1080/21645515.2023.2289242.

Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2.

Mariz FC, Putzker K, Sehr P, Müller M

Frontiers in immunology, 2023

doi:10.3389/fimmu.2023.1272018.

Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.

Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, Rani Reddy Poli U, Malvi SG, Esmy PO, Lucas E, Verma Y, Shah A, Zomawia E, Pimple S, Jayant K, Hingmire S, Chiwate A, Divate U, Vashist S, Mishra G, Jadhav R, Siddiqi M, Sankaran S, Pillai Rameshwari Ammal Kannan T, Kartha P, Shastri SS, Sauvaget C, Radhakrishna Pillai M, Waterboer T, Müller M, Sehr P, Unger ER, Sankaranarayanan R, Basu P

Vaccine, 2022

doi:10.1016/j.vaccine.2022.11.044.

Structural basis for tunable affinity and specificity of LxCxE-dependent protein interactions with the retinoblastoma protein family.

Putta S, Alvarez L, Lüdtke S, Sehr P, Müller GA, Fernandez SM, Tripathi S, Lewis J, Gibson TJ, Chemes LB, Rubin SM

Structure , 2022

doi:10.1016/j.str.2022.05.019.

First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement.

Herp D, Ridinger J, Robaa D, Shinsky SA, Schmidtkunz K, Yesiloglu TZ, Bayer T, Steimbach RR, Herbst-Gervasoni CJ, Merz A, Romier C, Sehr P, Gunkel N, Miller AK, Christianson DW, Oehme I, Sippl W, Jung M

Chembiochem : a European journal of chemical biology, 2022

doi:10.1002/cbic.202200180.

Short peptide pharmacophores developed from protein phosphatase-1 disrupting peptides (PDPs).

Fontanillo M, Trebacz M, Reinkemeier CD, Avilés Huerta D, Uhrig U, Sehr P, Köhn M

Bioorganic & medicinal chemistry, 2022

doi:10.1016/j.bmc.2022.116785.

Molecular basis of mRNA transport by a kinesin-1-atypical tropomyosin complex.

Dimitrova-Paternoga L, Jagtap PKA, Cyrklaff A, Vaishali, Lapouge K, Sehr P, Perez K, Heber S, Löw C, Hennig J, Ephrussi A

Genes & development, 2021

doi:10.1101/gad.348443.121.

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.

Mariz FC, Gray P, Bender N, Eriksson T, Kann H, Apter D, Paavonen J, Pajunen E, Prager KM, Sehr P, Surcel HM, Waterboer T, Müller M, Pawlita M, Lehtinen M

The Lancet. Infectious diseases, 2021

doi:10.1016/S1473-3099(20)30873-2.

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.

Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, Prabhu PR, Sankaranarayanan R, Eriksson T, Pawlita M, Prager K, Sehr P, Waterboer T, Müller M, Lehtinen M

NPJ vaccines, 2020

doi:10.1038/s41541-020-0165-x.

Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.

Tsang SH, Basu P, Bender N, Herrero R, Kemp TJ, Kreimer AR, Müller M, Panicker G, Pawlita M, Pinto LA, Sampson JN, Sankaranarayanan R, Schussler J, Sehr P, Sierra MS, Waterboer T, Unger ER, Hildesheim A, Hildesheim A

Vaccine, 2020

doi:10.1016/j.vaccine.2020.07.017.

Design and synthesis of dihydroxamic acids as HDAC6/8/10 inhibitors.

Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, Witt O, Oehme I, Herbst-Gervasoni CJ, Osko JD, Porter NJ, Christianson DW, Gunkel N, Miller AK

ChemMedChem, 2020

doi:10.1002/cmdc.202000149.

Loss of N-glycanase 1 alters transcriptional and translational regulation in K562 cell lines.

Mueller WF, Jakob P, Sun H, Clauder-Münster S, Ghidelli-Disse S, Ordonez D, Boesche M, Bantscheff M, Collier P, Haase B, Benes V, Paulsen M, Sehr P, Lewis J, Drewes G, Steinmetz LM

G3 (Bethesda, Md.), 2020

doi:10.1534/g3.119.401031.

Small-molecule-mediated chemical knock-down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure.

Adams V, Bowen TS, Werner S, Barthel P, Amberger C, Konzer A, Graumann J, Sehr P, Lewis J, Provaznik J, Benes V, Büttner P, Gasch A, Mangner N, Witt CC, Linke A, Labeit D, Labeit S

Journal of cachexia, sarcopenia and muscle, 2019

doi:10.1002/jcsm.12448.

A time-resolved live cell imaging assay to identify small molecule inhibitors of FGF2 signaling.

Ahmed M, Legrand C, Yagüe Relimpio A, Beretta CA, Muschko A, Wegehingel S, Müller HM, Sehr P, Will DW, Lewis JD, Nickel W

FEBS letters, 2019

doi:10.1002/1873-3468.13462.

Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.

Géraldy M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, Oehme I, Witt O, Malz M, Nogueira MS, Koch O, Gunkel N, Miller AK

Journal of medicinal chemistry, 2019

doi:10.1021/acs.jmedchem.8b01936.

Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow up cohort study.

Basu P, Muwonge R, Bhatla N, Nene BM, Joshi S, Esmy PO, Poli URR, Joshi G, Verma Y, Zomawia E, Shastri SS, Pimple S, Anantharaman D, Prabhu PR, Hingmire S, Lucas E, Sauvaget C, Gheit T, Pawlita M, Malvi SG, Jayant K, Michel A, Siddiqi M, Sankaran S, Butt J, Varghese R, Rameshwari Ammal Kannan TP, Willhauck-Fleckenstein M, Divate U, Müller M, Waterboer T, Mishra G, Jadhav R, Sehr P, Vashist S, Thorat R, Tommasino M, Pillai MR, Sankaranarayanan R

Papillomavirus research (Amsterdam, Netherlands), 2019

doi:10.1016/j.pvr.2019.01.004.

Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.

Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, Verma Y, Zomawia E, Pimple S, Tommasino M, Pawlita M, Gheit T, Waterboer T, Sehr P, Pillai MR

Vaccine, 2018

doi:10.1016/j.vaccine.2018.02.087.

Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in India.

Bhatla N, Nene BM, Joshi S, Esmy PO, Poli URR, Joshi G, Verma Y, Zomawia E, Pimple S, Prabhu PR, Basu P, Muwonge R, Hingmire S, Sauvaget C, Lucas E, Pawlita M, Gheit T, Jayant K, Malvi SG, Siddiqi M, Michel A, Butt J, Subha Sankaran J, Kannan TPRA, Varghese R, Divate U, Willhauck-Fleckenstein M, Waterboer T, Müller M, Sehr P, Kriplani A, Mishra G, Jadhav R, Thorat R, Tommasino M, Radhakrishna Pillai M, Sankaranarayanan R

Papillomavirus research (Amsterdam, Netherlands), 2018

doi:10.1016/j.pvr.2018.03.008.

Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.

Bowen TS, Adams V, Werner S, Fischer T, Vinke P, Brogger MN, Mangner N, Linke A, Sehr P, Lewis J, Labeit D, Gasch A, Labeit S

Journal of cachexia, sarcopenia and muscle, 2017

doi:10.1002/jcsm.12233.

Small molecule inhibitors targeting Tec kinase block unconventional secretion of fibroblast growth factor 2.

La Venuta G, Wegehingel S, Sehr P, Müller HM, Dimou E, Steringer JP, Grotwinkel M, Hentze N, Mayer MP, Will DW, Uhrig U, Lewis JD, Nickel W

The Journal of biological chemistry, 2016

doi:10.1074/jbc.M116.729384.

Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.

Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, Østergaard L, Tolstrup M, Dillner J

Vaccine, 2016

doi:10.1016/j.vaccine.2016.02.019.

Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds

Machara A, Lux V, Kozisek M, Saskova KG, Stepanek O, Kotora M, Parkan K, Pavova M, Glass B, Sehr P, Lewis J, Mueller B, Krausslich HG, Konvalinka J

JOURNAL OF MEDICINAL CHEMISTRY, 2015

doi:10.1021/acs.jmedchem.5b01089.

Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, Jivarajani P, Verma Y, Zomawia E, Siddiqi M, Shastri SS, Jayant K, Malvi SG, Lucas E, Michel A, Butt J, Vijayamma JMB, Sankaran S, Kannan TPRA, Varghese R, Divate U, Thomas S, Joshi G, Willhauck-Fleckenstein M, Waterboer T, Muller M, Sehr P, Hingmire S, Kriplani A, Mishra G, Pimple S, Jadhav R, Sauvaget C, Tommasino M, Pillai MR

LANCET ONCOLOGY, 2016

doi:10.1016/S1470-2045(15)00414-3.

A direct role for ATP1A1 in unconventional secretion of fibroblast growth factor 2.

Zacherl S, La Venuta G, Müller HM, Wegehingel S, Dimou E, Sehr P, Lewis JD, Erfle H, Pepperkok R, Nickel W

The Journal of biological chemistry, 2015

doi:10.1074/jbc.m114.590067.

The E6AP Binding Pocket of the HPV16 E6 Oncoprotein Provides a Docking Site for a Small Inhibitory Peptide Unrelated to E6AP, Indicating Druggability of E6.

Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, Hoppe-Seyler K, Travé G, Hoppe-Seyler F

PloS one, 2014

doi:10.1371/journal.pone.0112514.

Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruses types 16 and 18

Brown D, Müller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A

Vaccine, 2014

doi:10.1016/j.vaccine.2014.08.004.

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.

Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS

The Journal of infectious diseases, 2013

doi:10.1093/infdis/jit657.

Comparison of the immunogenicity of Cervarix(®) and Gardasil(®) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33 and HPV-45 in HIV-infected adults.

Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Ostergaard L, Søgaard OS

Human vaccines & immunotherapeutics, 2014

doi:10.4161/hv.27925.

Structural basis for targeting the chromatin repressor Sfmbt to Polycomb response elements.

Alfieri C, Gambetta MC, Matos R, Glatt S, Sehr P, Fraterman S, Wilm M, Müller J, Müller CW

Genes & development, 2013

doi:10.1101/gad.226621.113.

New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain

Pautus S, Sehr P, Lewis J, Fortuné A, Wolkerstorfer A, Szolar O, Guilligay D, Lunardi T, Décout JL, Cusack S

Journal of medicinal chemistry, 2013

doi:10.1021/jm401369y.

High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses

Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Müller L, Pawlita M, Müller M

PloS one, 2013

doi:10.1371/journal.pone.0075677.

Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation

Casanova CM, Sehr P, Putzker K, Hentze MW, Neumann B, Duncan KE, Thoma C

PloS one, 2012

doi:10.1371/journal.pone.0045943.

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M, Michaelis U, Roden RB, Gissmann L, Kleinschmidt JA

PloS one, 2012

doi:10.1371/journal.pone.0039741.

Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein

Simon B, Kirkpatrick JP, Eckhardt S, Reuter M, Rocha EA, Andrade-Navarro MA, Sehr P, Pillai RS, Carlomagno T

Structure (London, England : 1993), 2011

doi:10.1016/j.str.2010.11.015.

The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies

Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, Tommasino M, Ottonello S, Müller M

Virology, 2011

doi:10.1016/j.virol.2010.10.017.

A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein

Dymalla S, Scheffner M, Weber E, Sehr P, Lohrey C, Hoppe-Seyler F, Hoppe-Seyler K

Journal of molecular medicine (Berlin, Germany), 2009

doi:10.1007/s00109-008-0432-1.

Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein

Bartonova V, Igonet S, Sticht J, Glass B, Habermann A, Vaney MC, Sehr P, Lewis J, Rey FA, Kraüsslich HG

The Journal of biological chemistry, 2008

doi:10.1074/jbc.m804230200.

The structural basis for cap binding by influenza virus polymerase subunit PB2

Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P, Lewis J, Ruigrok RW, Ortin J, Hart DJ, Cusack S

Nature structural & molecular biology, 2008

doi:10.1038/nsmb.1421.

Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen

Sehr P, Pawlita M, Lewis J

Journal of biomolecular screening, 2007

doi:10.1177/1087057107301246.